Adverse Events Of Atovaquone-Proguanil Compared With Mefloquine as Malaria Chemoprophylaxis Used By Visitors Of Malaria Endemic Country : A Systematic Review And Meta Analysis
DOI:
https://doi.org/10.53366/jimki.v12i1.849Keywords:
Adverse Event, Atovaquone-Proguanil, Malaria, Mefloquine, TravelersAbstract
Introduction: Chemoprophylaxis plays a crucial role in preventing malaria among travellers to endemic regions. Atovaquone-proguanil and mefloquine are two of the main chemoprophylactic agents recommended by the WHO and CDC to prevent malaria. Both are effective in malaria prophylaxis but are associated with distinct adverse events that can influence their use in travellers.
Method: Literature search was conducted in ScienceDirect, and PubMed databases until 2025 without language constraints. Inclusion criteria focused on studies assessed the use of both atovaquone-proguanil and mefloquine as malaria prophylaxis in visitors to malaria-endemic countries. The risk of bias was evaluated using TheNewcastle-Ottawa Scale and Cochrane "RoB" tool.
Discussion: A total of 10 studies were included and resulting in 15 categories of adverse events. Reported events were diarrhea (RR 1.07; 95% CI; p = 0.72) mouth ulcers (RR 2.88; 95% CI; p = 0,32), indigestion (RR 1.17; 95% CI; p = 0.80), abdominal pain (RR 1.41; 95% CI; p = 0.10), vomiting & Nausea (RR 0.64; 95% CI; p = 0.16), insomnia (RR 0.25; 95% CI; p = 0.007), dizziness/vertigo (RR 0.41; 95% CI; p = 0.02), tinnitus (RR 0.70, 95% CI; p < 0.00001), anxiety (RR 0.13; 95% CI; p < 0.00001), depression (RR 0.20; 95% CI; p < 0.00001), nightmares (RR 0.18; 95% CI; p = 0.001), headaches (RR 0.47; 95% CI; p = 0.003), dermatological effects (RR 0.89; 95% CI; p = 0.74), eye disorders (RR 0.42; 95% CI; p = 0.02), and a pooled analysis along with events not specifically mentioned (RR 0.38; 95% CI; p = 0.33). Heterogeneity among included studies was generally low to moderate.
Conclusion: Practically, mefloquine is suitable for long-term weekly prophylaxis except for those with psychiatric disorders, whereas atovaquone-proguanil is preferred for short-term travel with the recommendation to administer it with food.
References
1. World Tourism Organization. Tourism Statistics-Country Fact Sheet [Internet]. World Tourism Organization2022 [cited 2025 Apr 12];Available from: https://www.unwto.org/statistics/country-fact-sheets
2. Charan S, Prakash A, Medhi B. Travel medicine – A comprehensive guide to safe world travel. Indian J Pharmacol 2023;55(6):351–5.
3. Asawapaithulsert P, Flaherty GT, Piyaphanee W. Trend Analysis of Travel Medicine Topics Presented at an International Tropical Medicine Conference. Am J Trop Med Hyg 2022;107(2):492–4.
4. Li J, Docile HJ, Fisher D, Pronyuk K, Zhao L. Current Status of Malaria Control and Elimination in Africa: Epidemiology, Diagnosis, Treatment, Progress and Challenges. J Epidemiol Glob Health 2024;14(3):561–79.
5. Shahbodaghi SD, Rathjen NA. Malaria: Prevention, Diagnosis, and Treatment. Am Fam Physician 2022;106(3):270–8.
6. Mertens JE. A History of Malaria and Conflict. Parasitol Res 2024;123(3):165.
7. Sypniewska P, Duda JF, Locatelli I, Althaus CR, Althaus F, Genton B. Clinical and laboratory predictors of death in African children with features of severe malaria: a systematic review and meta-analysis. BMC Med 2017;15(1):147.
8. Venkatesan P. The 2023 WHO World malaria report. Lancet Microbe 2024;5(3):e214.
9. Nemhauser JB, editor. CDC Yellow Book 2024. Oxford University PressNew York; 2023.
10. Westercamp N, Arguin PM. Malaria chemoprophylaxis: A proven public health intervention for international travelers. Travel Med Infect Dis 2015;13(1):8–9.
11. World Health Organization. International travel and health. Module 3. Malaria. Geneva: 2024.
12. Westercamp N, Arguin PM. Malaria chemoprophylaxis: A proven public health intervention for international travelers. Travel Med Infect Dis 2015;13(1):8–9.
13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;n71.
14. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019.
15. Kepes S, Wang W, Cortina JM. Heterogeneity in Meta-Analytic Effect Sizes: An Assessment of the Current State of the Literature. Organ Res Methods 2024;27(3):369–413.
16. Stoney RJ, Chen LH, Jentes ES, Wilson ME, Han P V., Benoit CM, et al. Malaria Prevention Strategies: Adherence Among Boston Area Travelers Visiting Malaria-Endemic Countries. The American Society of Tropical Medicine and Hygiene 2016;94(1):136–42.
17. Laverone E, Boccalini S, Bechini A, Belli S, Santini MG, Baretti S, et al. Travelers’ Compliance to Prophylactic Measures and Behavior During Stay Abroad: Results of a Retrospective Study of Subjects Returning to a Travel Medicine Center in Italy. J Travel Med 2006;13(6):338–44.
18. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, et al. Atovaquone‐Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travelers: Results from a Randomized, Double‐Blind Study. Clinical Infectious Diseases 2001;33(7):1015–21.
19. Andersson H, Askling HH, Falck B, Rombo L. Well-Tolerated Chemoprophylaxis Uniformly Prevented Swedish Soldiers from Plasmodium falciparum Malaria in Liberia, 2004–2006. Mil Med 2008;173(12):1194–8.
20. Landman KZ, Tan KR, Arguin PM. Adherence to malaria prophylaxis among Peace Corps Volunteers in the Africa region, 2013. Travel Med Infect Dis 2015;13(1):61–8.
21. Tuck J, Williams J. Malaria protection in Sierra Leone during the Ebola outbreak 2014/15; The UK military experience with malaria chemoprophylaxis Sep 14–Feb 15. Travel Med Infect Dis 2016;14(5):471–4.
22. Schneider C, Adamcova M, Jick SS, Schlagenhauf P, Miller MK, Rhein HG, et al. Use of anti-malarial drugs and the risk of developing eye disorders. Travel Med Infect Dis 2014;12(1):40–7.
23. Cunningham J, Horsley J, Patel D, Tunbridge A, Lalloo DG. Compliance with long-term malaria prophylaxis in British expatriates. Travel Med Infect Dis 2014;12(4):341–8.
24. Reinsberg F, Moehlmann MW, Krumkamp R, Landsmann L, Heitkamp C, Jochum J, et al. Symptoms of illness during travel and risk factors for non-adherence to malaria prophylaxis—a cross-sectional study in travellers from Germany. J Travel Med 2023;30(3).
25. Eick-Cost AA, Hu Z, Rohrbeck P, Clark LL. Neuropsychiatric Outcomes After Mefloquine Exposure Among U.S. Military Service Members. The American Society of Tropical Medicine and Hygiene 2017;96(1):159–66.
26. Schnyder JL, de Jong HK, Bache EB, van Hest RM, Schlagenhauf P, Borrmann S, et al. On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives. Travel Med Infect Dis 2023;52:102520.
27. Savelkoel J, Binnendijk KH, Spijker R, van Vugt M, Tan K, Hänscheid T, et al. Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: A systematic review. Travel Med Infect Dis 2018;21:3–20.
28. Freedman DO, Chen LH, Kozarsky PE. Medical Considerations before International Travel. N Engl J Med 2016;375(3):247–60.
29. Ahmad SS, Rahi M, Ranjan V, Sharma A. Mefloquine as a prophylaxis for malaria needs to be revisited. Int J Parasitol Drugs Drug Resist 2021;17:23–6.
30. Martins AC, Paoliello MMB, Docea AO, Santamaria A, Tinkov AA, Skalny A V., et al. Review of the mechanism underlying mefloquine-induced neurotoxicity. Crit Rev Toxicol 2021;51(3):209–16.
31. Lim LY, Go ML. THE ANTICHOLINESTERASE ACTIVITY OF MEFLOQUINE. Clin Exp Pharmacol Physiol 1985;12(5):527–31.
32. Petrov KA, Nikolsky EE, Masson P. Autoregulation of Acetylcholine Release and Micro-Pharmacodynamic Mechanisms at Neuromuscular Junction: Selective Acetylcholinesterase Inhibitors for Therapy of Myasthenic Syndromes. Front Pharmacol 2018;9.
33. Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Curr Neuropharmacol 2013;11(3):315–35.
34. Ijomone OM, Aluko OM, Okoh COA, Martins AC, Aschner M. Role for calcium signaling in manganese neurotoxicity. Journal of Trace Elements in Medicine and Biology 2019;56:146–55.
35. Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, et al. Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro. Psychopharmacology (Berl) 2014;231(14):2771–83.
36. Nevin RL. A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine are serious adverse reactions. Pharmacol Res Perspect 2017;5(4).
37. Walzer PD, Smulian AG, Miller RF. Pneumocystosis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice. Elsevier; 2011. page 608–13.
38. Nixon GL, Moss DM, Shone AE, Lalloo DG, Fisher N, O’Neill PM, et al. Antimalarial pharmacology and therapeutics of atovaquone. Journal of Antimicrobial Chemotherapy 2013;68(5):977–85.
39. White NJ. Malaria. In: Manson’s Tropical Diseases. Elsevier; 2024. page 569–617.
40. Lochner M, Thompson AJ. The Antimalarial Drug Proguanil Is an Antagonist at 5-HT3 Receptors. J Pharmacol Exp Ther 2014;351(3):674–84.
41. Thompson AJ, Lummis SCR. Antimalarial drugs inhibit human 5‐HT3 and GABA A but not GABA C receptors. Br J Pharmacol 2008;153(8):1686–96.
42. Xie Z, Zhang X, Zhao M, Huo L, Huang M, Li D, et al. The gut-to-brain axis for toxin-induced defensive responses. Cell 2022;185(23):4298-4316.e21.
43. Farkouh CS, Anthony MR, Amatul F, Abdi P, Ali Khan Q. The Intersection Between Malaria Treatment and Chemoprophylaxis and Their Potential Adverse Dermatologic Manifestations: A Narrative Review. Cureus 2023;
44. Fukasawa T, Yoshizaki-Ogawa A, Enomoto A, Miyagawa K, Sato S, Yoshizaki A. Pharmacotherapy of Itch—Antihistamines and Histamine Receptors as G Protein-Coupled Receptors. Int J Mol Sci 2022;23(12):6579.
45. Quinn JC. Complex Membrane Channel Blockade: A Unifying Hypothesis for the Prodromal and Acute Neuropsychiatric Sequelae Resulting from Exposure to the Antimalarial Drug Mefloquine. J Parasitol Res 2015;2015:1–12.
46. Adamcova M, Schaerer MT, Bercaru I, Cockburn I, Rhein HG, Schlagenhauf P. Eye disorders reported with the use of mefloquine (Lariam®) chemoprophylaxis – A drug safety database analysis. Travel Med Infect Dis 2015;13(5):400–8.
47. Milatovic D, Zaja-Milatovic S, Breyer RM, Aschner M, Montine TJ. Neuroinflammation and oxidative injury in developmental neurotoxicity. In: Reproductive and Developmental Toxicology. Elsevier; 2011. page 847–54.
48. Terrell AG, Forde ME, Firth R, Ross DA. Malaria Chemoprophylaxis and Self-Reported Impact on Ability to Work: Mefloquine Versus Doxycycline. J Travel Med 2015;22(6):383–8.
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 Jerroll Septian Tammubua, Made Kurnia Widiastuti Giri, Made Ayu Rahayu Agastyane Rahmadewi, I Made Lingga Tresnadinata, Ni Putu Cempaka Pradnyadewi Pradnyadewi, Made Devina Febryanti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.